JP2011503199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503199A5 JP2011503199A5 JP2010534194A JP2010534194A JP2011503199A5 JP 2011503199 A5 JP2011503199 A5 JP 2011503199A5 JP 2010534194 A JP2010534194 A JP 2010534194A JP 2010534194 A JP2010534194 A JP 2010534194A JP 2011503199 A5 JP2011503199 A5 JP 2011503199A5
- Authority
- JP
- Japan
- Prior art keywords
- heterocyclic
- condensed
- nhr
- benzene
- cycloalkane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98847907P | 2007-11-16 | 2007-11-16 | |
| US60/988,479 | 2007-11-16 | ||
| PCT/US2008/083478 WO2009064938A1 (en) | 2007-11-16 | 2008-11-14 | Method of treating arthritis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013232754A Division JP5667684B2 (ja) | 2007-11-16 | 2013-11-11 | 関節炎の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011503199A JP2011503199A (ja) | 2011-01-27 |
| JP2011503199A5 true JP2011503199A5 (enExample) | 2012-01-05 |
| JP5450434B2 JP5450434B2 (ja) | 2014-03-26 |
Family
ID=40291332
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010534194A Expired - Fee Related JP5450434B2 (ja) | 2007-11-16 | 2008-11-14 | 関節炎の治療方法 |
| JP2013232754A Expired - Fee Related JP5667684B2 (ja) | 2007-11-16 | 2013-11-11 | 関節炎の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013232754A Expired - Fee Related JP5667684B2 (ja) | 2007-11-16 | 2013-11-11 | 関節炎の治療方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20090176785A1 (enExample) |
| EP (1) | EP2231159A1 (enExample) |
| JP (2) | JP5450434B2 (enExample) |
| KR (1) | KR101585848B1 (enExample) |
| CN (1) | CN101969951B (enExample) |
| AU (1) | AU2008322595B2 (enExample) |
| CA (1) | CA2705294C (enExample) |
| DO (1) | DOP2013000169A (enExample) |
| IL (2) | IL205501A (enExample) |
| MX (1) | MX2010005395A (enExample) |
| NZ (2) | NZ601350A (enExample) |
| RU (2) | RU2472509C2 (enExample) |
| WO (1) | WO2009064938A1 (enExample) |
| ZA (1) | ZA201003434B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| RU2015141713A (ru) * | 2010-03-25 | 2018-12-28 | Эббви Инк. | Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| CA3152557A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| PT2643322T (pt) | 2010-11-23 | 2017-11-13 | Abbvie Inc | Sais e formas cristalinas de um agente indutor de apoptose |
| ES2603129T3 (es) | 2010-11-23 | 2017-02-23 | Abbvie Ireland Unlimited Company | Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2 |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN111511748B (zh) | 2017-08-23 | 2023-05-02 | 广州麓鹏制药有限公司 | Bcl-2抑制剂 |
| US11903950B2 (en) | 2018-08-22 | 2024-02-20 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| US20220372042A1 (en) | 2019-10-03 | 2022-11-24 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| KR20220098755A (ko) | 2019-11-05 | 2022-07-12 | 애브비 인코포레이티드 | 나비토클락스를 사용한 골수섬유증 및 mpn 관련 장애 치료에 사용하기 위한 투약 레지멘 |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| JP7849296B2 (ja) | 2020-02-24 | 2026-04-21 | グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド | Ｂｃｌ２阻害剤を含むホットメルト押出し固体分散体 |
| US20240166646A1 (en) | 2020-12-22 | 2024-05-23 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9200275D0 (en) * | 1992-01-08 | 1992-02-26 | Roussel Lab Ltd | Chemical compounds |
| WO1997013751A1 (en) * | 1995-10-10 | 1997-04-17 | Pfizer Inc. | Indole carbamates as leukotriene antagonists |
| NZ520657A (en) * | 2000-03-21 | 2004-11-26 | Procter & Gamble | Heterocyclic side chain containing, N-substituted metalloprotease inhibitors |
| AU9598601A (en) * | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| GB0217431D0 (en) * | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| ATE403654T1 (de) * | 2003-07-28 | 2008-08-15 | Janssen Pharmaceutica Nv | Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren |
| KR100747401B1 (ko) * | 2003-09-03 | 2007-08-08 | 화이자 인코포레이티드 | 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물 |
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| ES2257929B1 (es) * | 2004-07-16 | 2007-05-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos. |
| PL1888550T3 (pl) * | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| US20060276464A1 (en) * | 2005-05-13 | 2006-12-07 | Wyeth | Diarylsulfone sulfonamides and use thereof |
| US20080182845A1 (en) * | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
-
2008
- 2008-11-14 CA CA2705294A patent/CA2705294C/en not_active Expired - Fee Related
- 2008-11-14 RU RU2010123796/15A patent/RU2472509C2/ru not_active IP Right Cessation
- 2008-11-14 US US12/270,987 patent/US20090176785A1/en not_active Abandoned
- 2008-11-14 EP EP08850262A patent/EP2231159A1/en not_active Withdrawn
- 2008-11-14 JP JP2010534194A patent/JP5450434B2/ja not_active Expired - Fee Related
- 2008-11-14 AU AU2008322595A patent/AU2008322595B2/en not_active Ceased
- 2008-11-14 CN CN2008801242231A patent/CN101969951B/zh not_active Expired - Fee Related
- 2008-11-14 NZ NZ601350A patent/NZ601350A/xx not_active IP Right Cessation
- 2008-11-14 KR KR1020107013163A patent/KR101585848B1/ko not_active Expired - Fee Related
- 2008-11-14 NZ NZ585085A patent/NZ585085A/xx not_active IP Right Cessation
- 2008-11-14 RU RU2012143212/15A patent/RU2526201C2/ru not_active IP Right Cessation
- 2008-11-14 WO PCT/US2008/083478 patent/WO2009064938A1/en not_active Ceased
- 2008-11-14 MX MX2010005395A patent/MX2010005395A/es active IP Right Grant
-
2010
- 2010-05-02 IL IL205501A patent/IL205501A/en not_active IP Right Cessation
- 2010-05-14 ZA ZA2010/03434A patent/ZA201003434B/en unknown
-
2013
- 2013-07-23 DO DO2013000169A patent/DOP2013000169A/es unknown
- 2013-07-24 IL IL227641A patent/IL227641A0/en unknown
- 2013-11-11 JP JP2013232754A patent/JP5667684B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-17 US US14/972,429 patent/US20160101109A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503199A5 (enExample) | ||
| RU2012143212A (ru) | Способ лечения артрита | |
| RU2011134634A (ru) | Индуцирующие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP5517935B2 (ja) | 細胞壊死阻害剤としてのインドール及びインダゾール化合物 | |
| AU2016256728B2 (en) | Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions | |
| JP2016534134A5 (enExample) | ||
| PE20210402A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| JP2014511869A5 (enExample) | ||
| RU2356893C2 (ru) | Ингибиторы фосфодиэстеразы 4 | |
| JP2014501732A5 (enExample) | ||
| JP2005526723A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| JP2012522003A5 (enExample) | ||
| RU2011134631A (ru) | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP2018526413A5 (enExample) | ||
| JP2014521653A5 (enExample) | ||
| JP2016530322A5 (enExample) | ||
| RU2015111133A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2013532709A5 (enExample) | ||
| JP2017503765A5 (enExample) | ||
| JP2016540771A5 (enExample) | ||
| BR112018069461A2 (pt) | nova forma cristalina de sal de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina salt | |
| JP2018503661A5 (enExample) | ||
| JP2010527985A5 (enExample) | ||
| JP2019535825A5 (enExample) |